(
For more information please visit: http://inhalation.se/investors/finansiella-rapporter/
Summary of the interim report
ISAB submitted an application for the clinical validation of PreciseInhale in early April and received approval from the
The company signed exclusive distribution agreements with key markets such as
With the support of an authorization from the Annual General Meeting on
CEO statement
Q2 2021 was a very eventful quarter for ISAB. I am very proud of what we have accomplished so far this year, which also lays the foundation for our continued work in the coming months.
- Thanks to solid and extensive preparatory work, we received approval from the
Medical Products Agency for our planned clinical study in mid-May. This work will continue for the rest of the year and we look forward to results in the form of data that will open up the clinical market for the company's technology. - The first meeting with ISAB's new "advisory board" took place during the second quarter. We received very good input and confirmation of how unique our platform is. As one of our advisory experts put it: "You are the only company that knows how much is dosed in the lung and how much stays there, because you measure it!"
-
We are highly involved in vaccine research against COVID-19 and in June, we signed a new contract research with
ISR Immune System Regulation AB for a value of about 900 KSEK. -
We also signed new distribution agreements in key markets such as
Japan andIndia . We look forward to collaborations with these reputable distributors that will lead to additional sales of at leastSEK 10 million over the next 18 months to ISAB. -
Through our partners in the
USA we have processed several potential customers in the market and after a few weeks we already received a new contract research assignment with a new customer worth overSEK 1 million . -
Last but not least, we ensured a good financial position for the company through a directed issue that provided ISAB with approximately
SEK 27.5 million before issue costs. This money is set aside for our expansion plans and continued commercialization of PreciseInhale technology with associated modules.
On the profit side for the first half of 2021, we have had increased costs of approximately
Even though sales in Q2 and so far this year have not been in line with our expectations, we have with us approximately
An exciting autumn with a series of activities awaits us. We are well prepared to take on the opportunities and deliver added value for our owners, partners and customers.
Huddinge
Manoush Masarrat
CEO
For more information about Inhalation Sciences, please contact:
Manoush Masarrat, CEO
E-mail: Manoush.masarrat@inhalation.se
Mobile: +46 (0)73 628 9153
About
The information was provided, through the company's CEO, for publication on
https://news.cision.com/inhalation-sciences/r/inhalation-sciences-sweden-ab--publ--releases-q2-report-2021,c3403353
https://mb.cision.com/Main/15842/3403353/1459109.pdf
https://mb.cision.com/Public/15842/3403353/bb6c2d6398d3a9bd.pdf
(c) 2021 Cision. All rights reserved., source